Introduction
Historically wrought in controversy, numerous studies in experimental model systems have in the past decade provided strong evidence for a role of the immune system in controlling spontaneously occurring cancers. 1 In this regard, perforin-deficient mice have been reported to spontaneously develop B-cell lymphomas, implicating lymphocyte cytotoxicity in immunosurveillance of hematologic malignancies. 2 In humans, perforin-deficiency caused by hypomorphic mutations in PRF1 have been associated with hematologic malignancies, ranging from lymphoma to leukemia, in children and adults.
Immunohistochemistry
Immunohistochemical stains were performed on deparaffinized tissue sections in a semi-automated manner with Bond Polymer Refine and Bond DAB Enhance on a Bond-Max stainer, as recommended by the manufacturer (Vision Biosystems, Leica Microsystems). Anti-CD3 (LN10, Novocastra), anti-CD8 (4B11, Novocastra), anti-CD15 (Carb-3, Dako), anti-CD20 (L26, Dako), anti-CD30 (1G12, Novocastra), anti-CD68 (PG-M1, Dako), antiBcl2 (3.1, Novocastra), anti-Ki67 (MIB-1, Dako), anti-PAX5 (1EW, Novocastra), anti-perforin (5B10, Novocastra), and anti-granzyme B (11F1, Novocastra) antibodies were used. Fluorescence in situ hybridization for EBV-encoded RNA (EBER) was also performed on a Bond-Max stainer, using fluorescein-conjugated oligonucleotide probes (EBER Probe, Leica Biosystems).
Functional assays
For assessment of NK cell-mediated cytotoxicity, a standard 4-h 51 Cr assay was used. 9 A value below 10 LU was considered pathological. 6 Cytotoxic lymphocyte exocytosis was assessed by flow cytometric quantification of CD107a surface expression on gated CD3 -
CD56
+ natural killer (NK) and CD3 + CD8 + CD57 + effector T cells in response to incubation with different target cells, as previously described. 10 To quantify responses to EBV, PBMC were mixed with synthetic peptides pools of LMP-1, BZLF-1, or EBNA-3A (all JPT Technologies), incubated for 6 h with GolgiPlug (BD Bioscience) added after 1 h, followed by extracellular staining of lineage markers and CD107a and intracellular staining of TNF-α. All samples were acquired on a LSR Fortessa cell analyzer (BD Biosciences) and analyzed using Flowjo 9.4 (Tree Star).
Results and Discussion
We have already detailed the clinical presentation of a 17-year old previously healthy girl carrying biallelic STXBP2 mutations c.1294C>A (p.Gln432X) and c.1634C>T (p.Ser545Leu). 11 The combination of the mutations causes a loss of Munc18-2 expression, the protein encoded by STXBP2 (Figure 1) . Briefly, the patient developed a life-threatening HLH triggered by a primary EBV infection and was successfully treated with immunochemotherapy according to a modification of the HLH-94 protocol. 12 Following treatment, the patient was administered intravenous immunoglobulin once a month due to hypogammaglobulinemia. Since completion of treatment, the patient remained in remission of HLH and did well.
At the age of 20 years, 45 months after the clinical presentation of HLH, the patient developed a rapidly progressive unilateral swelling of the neck (Figure 2A ). The patient complained of malaise and drowsiness, but denied fever, sweating or weight loss. Computed structure effaced by lymphohistiocytic proliferation ( Figure 2C ). A population of dispersed, large atypical cells with Hodgkin-Reed-Sternberg (HRS) morphology could be identified ( Figure 2C ). These cells expressed PAX5, CD15, CD30, and Ki67, transcribed EBER, but were negative for CD3, CD20, and ALK1 ( Figure 2C and data not shown). Based on these findings, the patient was diagnosed with EBV + cHL stage IA of mixed cellularity type. The haematologica | 2013; 98(5) Experimental models have indicated important roles for NK and γδ T cells in perforin-mediated control of B-cell lymphomas. 13 Moreover, human tonsilar NK cells can restrict EBV-mediated transformation though IFN-γ production.
14 However, in our patient, among tumor infiltrating lymphocytes, very few CD56 + cells were observed, whereas CD3
+ and CD8 + cells were abundant, with many expressing granzyme B and/or perforin ( Figure 2C ,3A, and data not shown). Thus, the immunological response to the lymphoma cells appeared to be dominated by cytotoxic T cells (CTLs). Experimental models have shown a central role for CD8 + T cells in protective immunity to EBV. 15, 16 Longitudinal analyses of lymphocyte cytotoxicity in the patient demonstrated an absence of exocytosis and cytotoxicity by both CTL and NK cells ( Figure 3B,C) , which was partially restored by IL-2 stimulation ( Figure 3D ,E).
Relative to a healthy control, EBV-specific T cells in the patient produced TNF-α, but displayed impaired degranulation in response to BZLF-1 peptides ( Figure 3F ). Compared to healthy controls, in whom 78% of the TNF-α + CD8 + T cells also were CD107a + , only 14% of the TNF-α + CD8 + T cells were CD107a + in our patient. By comparison, peptide pools to EBNA-3A or LMP-1 did not elicit significant T-cell responses in the patient (data not shown). Of note, mouse models indicate tumor immunogenicity is dictated by oncogene expression. 17, 18 Whereas overexpression of Myc or loss of p53 does not confer immunogenicity, overexpression of Bcl-2 does. cHL cells in our patient expressed Bcl-2 ( Figure 3G ), possibly reflecting impaired immunological sculpting. [17] [18] [19] In summary, the present patient suggests the possibility of an association of hypomorphic STXBP2 mutations with lymphoma. The cumulative dose of etoposide received during HLH-therapy was low (0.2 g/m 2 ). Furthermore, etoposide-induced malignancies are typically myeloidderived. 20 Thus, impaired immunosurveillance of EBVinfected and transformed cells is a plausible cause of cHL in our patient. 21 Notably, we have previously reported development of acute myeloid leukemia and myelodysplastic syndrome in 2 STX11-deficient patients who received 3.1 and 23.9 g/m 2 of etoposide/teniposide, respectively, so these malignancies could also be secondary to chemotherapy. 22 Strengthening the notion of a causal link between defective exocytosis and lymphoma, Pagel and colleagues recently reported a patient homozygous for a c.1247-1G>C splice error mutation in STXBP2 who initially presented with cHL stage IIIB and HLH features at the age of nine years. 23 The patient was successfully treated for lymphoma, but an HLH relapse occurred at the age of ten years. Thus, similar to what has been reported in patients with biallelic mutations in PRF1 or LYST, which both impair lymphocyte cytotoxicity, 3, 4, 24 patients with severe biallelic mutations in STXBP2 that abrogate exocytosis most likely present with HLH in infancy, whereas patients with hypomorphic mutations may present with hematologic malignancies later in life. Notably, the present patient did not manifest HLH at the time of lymphoma development. Therefore, studies of the frequencies of mutations in FHL-associated genes are warranted in lymphoma patients. An interesting question is whether mutations in certain FHL-associated genes more strongly predispose to development of lymphoma than others. Although the genes are all required for lymphocyte cytotoxic function, PRF1 mutations do not prevent release of granzymes and other granule constituents, whereas mutations in UNC13D, STXBP2, and STX11 do. Whereas perforin-deficiency specifically impairs lymphocyte cytotoxicity, the latter genes also affect other exocytic, but non-cytotoxic, functions of diverse immune cells, as well as platelets. This may have consequences for susceptibility to lymphoma development.
These findings have important clinical implications. Allogeneic hematopoietic stem cell transplantation (HSCT) represents the only cure for FHL. The cumulative risk of HLH and malignancies should be taken into consideration when determining whether to perform HSCT. We, therefore, currently favor HSCT in patients with defined disease-causing mutations in FHL genes. A molecular diagnosis may be difficult to obtain in some patients, e.g. due to non-coding aberrations. 25 In this setting, reproducible defects in cytotoxic lymphocyte function also may warrant HSCT.
